India Pharma Outlook Team | Monday, 13 July 2026
Mankind Pharma has approved two major strategic decisions to sharpen its long-term growth strategy.
The company will sell its hospitality business for Rs 49 crore. It will also establish a wholly owned subsidiary in the Netherlands.
Mankind Pharma said the new overseas unit will focus on R&D, business development, and investments in niche therapies. The twin moves reflect the company's plan to exit non-core businesses while expanding its global pharmaceutical presence.
The decisions were approved during the company's Board of Directors meeting held on July 11. The details were later shared through a regulatory filing.
Mankind Pharma has approved the sale of its entire 100 percent stake in Broadway Hospitality Services Pvt. Ltd. to AKRK Projects LLP and Partners.
The deal is valued at Rs 49 crore. The amount is subject to customary closing adjustments. The transaction is expected to be completed within 90 days.
The company said the sale is part of its strategy to monetize non-core assets. It wants to focus more on its core pharmaceutical business.
According to the regulatory filing:
The company also clarified that the buyers are not part of its promoter or promoter group. It added that the transaction is not a related-party deal.
Also Read: The Strategic Role of Regional Corridors in Future-Ready MedTech
Alongside the divestment, Mankind Pharma approved the incorporation of a wholly owned subsidiary in the Netherlands.
The new entity will operate as a special purpose vehicle. It will hold investments in R&D assets. It will also pursue business development opportunities in niche therapies.
The company plans to invest up to Euro 5 million. The investment will be made in one or more tranches.
The funds will support:
The investment will follow the provisions of the Foreign Exchange Management Act (FEMA). It will also comply with Reserve Bank of India regulations. Regulatory requirements in the Netherlands will also be followed.
The latest decisions highlight Mankind Pharma's efforts to streamline its business portfolio. The company is reducing exposure to businesses outside its core operations.
At the same time, it is increasing investments in innovation-led growth. The Netherlands subsidiary is expected to help identify opportunities in specialty pharmaceuticals and advanced therapies.
By combining a non-core asset sale with fresh overseas investments, the company is preparing for future growth. The strategy also strengthens its global innovation footprint.
The Rs 49 crore divestment allows the company to unlock value from a smaller business. The new overseas subsidiary creates a platform for future R&D collaborations and strategic investments.
With these steps, Mankind Pharma is balancing portfolio optimization with long-term global expansion. The company is also strengthening its focus on research-driven pharmaceutical opportunities.
